Understand the source comparison
Peptides & Stem Cell Therapy Synergy: Protocol Comparison
Phase 1: Survival & Attachment Hours 0–72 post-implant IGF-1, BPC-157 Activate PI3K/Akt survival pathways; upregulate integrin expression to prevent anoikis Single dose at hour 0, optional repeat at hour 48 Essential. Stem cells are most vulnerable during init
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Phase 1: Survival & Attachment
- Hours 0–72 post-implant
- IGF-1, BPC-157
- Activate PI3K/Akt survival pathways; upregulate integrin expression to prevent anoikis
- Single dose at hour 0, optional repeat at hour 48
- Essential. Stem cells are most vulnerable during initial attachment; skipping this phase reduces engraftment by 40–60%
- Phase 2: Differentiation
- Days 4–14
- Cerebrolysin, P21, Dihexa
- Promote lineage-specific differentiation via neurotrophin receptor activation (TrkB, p75); enhance synaptic plasticity
- Single dose day 4, repeat day 10 if extended protocol
- Critical for neural or cognitive applications; unnecessary for mesenchymal lineages
- Phase 3: Immune Modulation
- Days −1 to 7
- Thymalin, KPV, LL-37
- Suppress NF-κB-mediated inflammation; normalize Treg populations; reduce cytokine-induced apoptosis
- Day −1 (Thymalin), day 2 (KPV), day 5 (Thymalin)
- Non-negotiable. Cytokine cascades peak 48–96 hours post-implant and cause majority of early cell death
- Concurrent (Avoid)
- Day 0 only
- All peptides mixed
- No phase-specific targeting; growth factors degraded before receptor upregulation; immune peptides miss cytokine peaks
- Single administration
- Least effective approach. Ignores cellular metabolic transitions and cytokine kinetics entirely